A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy

Trial Profile

A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Amlodipine (Primary) ; Celecoxib (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Kitov Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2017 According to a Kitov Pharmaceuticals media release, company has submitted a NDA to the U.S. FDA for KIT-302 and are on track to meet anticipated Prescription Drug User Fee Act (PDUFA) dates with respect to FDA filing the NDA in the third quarter of 2017, and rendering a decision on approval for marketing of KIT-302 during the second quarter of 2018
    • 26 Jun 2017 According to a Kitov Pharmaceuticals Holdings Ltd. media release, the company expects that the formal filing of the NDA by FDA will occur by the end of the third quarter of 2017.
    • 26 Jun 2017 According to a Kitov Pharmaceuticals Holdings Ltd. media release, the company has begun the process of digitizing the New Drug Application (NDA) for KIT-302.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top